|
Cell-based assays monitor changes in living cells in response to a wide variety of inducers and events, such as receptor activation, external stimuli and stress, drugs, and modulated gene and protein expression. The market for these assays and their applications is growing rapidly, with new advances in technology platforms and high throughput screening systems. Recent studies by the MRG reveal a 40% growth from last year, with the worldwide market worth a phenomenal $1.6 billion in 2007. The expansion of the cell-based assays market is derived from the need for elucidating the functions of millions of proteins, and for better medicine development. By employing bioassays in automated systems, characterisation of a large number of drug targets can be streamlined and the drug discovery process made more efficient. Cell-based assays are used in both academia and pharmaceutical R&D, and are an integral part of preclinical drug development. Bioassays increasingly facilitate the link between laboratory and clinic by identifying adverse effects. It is an optimum time to discover the techniques and methods you need to succeed with cell-based assays. SMi's Cell-Based Assays conference is designed to convey this knowledge and to reveal the latest technological developments in the area.
Critical challenges that will be addressed: - BIOASSAY DEVELOPMENT: Examine the requirements for efficient cell-based assay development
- NEW AND IMPROVED TECHNOLOGY PLATFORMS: Gain an insight into the latest advances in the technologies behind cell-based assays from imaging to biosensors
- CELL-BASED ASSAY APPLICATIONS: Explore the versatility of cell based assay applications in a multitude of fields
- HIGH THROUGHPUT CELL-BASED SCREENING: Understand multi-parallel, high throughput and array systems of cell-based assays and applications
- EXPANDING THE POTENTIAL: From detection methods and reporter assays to gene and protein function and drug target discovery
Expert speaker line-up includes:
- Oliver Nayler, Director, Head Molecular Cell Biology, Actelion Pharmaceuticals Ltd
- Willem Schoonen, Group Leader In Vitro Toxicology and Toxicogenomics, DMPK & Safety, Schering Plough Research Institute
- Rami Hannoush, Scientist, Protein Engineering, Genentech Inc
- Paul Lang, Head, Assay Development and Biomolecular Pharmacology, Merck Serono
- Marie-Claire Peakman, Senior Director, Cardiovascular, Metabolic and Endocrine Disease, Pfizer Global R&D
- Alison Griffen, Associate Team Leader, Cancer Bioscience, AstraZeneca
- Khalid Khabar, Director, Biomolecular Research, King Faisal Specialist Hospital and Research Centre
- Philip Denner, Screening, High-Content Analysis, Lead Discovery, Bayer Schering Pharma AG
- Vincent Unterreiner, Novartis Pharma AG
- David Ferrick, Chief Scientific Officer, Biology and Applications, Seahorse Bioscience Inc
- Laleh Safinia, Research Analyst, Frost & Sullivan
- Rob Howes, Research Director, Horizon Discovery Ltd
- Heather Baird Tomlinson, Senior Manager, Pharmaceutical Products, Diagnostic Hybrids
- Rosalyn Forsey, Biomarker Specialist, LCG Biosciences
- Rochdi Bouhelal, Research Investigator, Novartis Pharma AG
- Debbie Lane, Team Leader, High Throughput Screening, Research, Medimmune
- Patricia Harris, Executive Director of Worldwide Sales, Sales and Marketing, Diagnostic Hybrids
- Andreas Scheel, Head, Cellular Assays, Evotec AG
- Yoram Reiter, Head, Laboratory of Molecular Immunology, Technion - Israel Institute of Technology
Daniel D’Orazio, Research Investigator, Centre for Proteomic Chemistry / Expertise Platform Kinases, Novartis Catherine Booth, Founder and MD Contract Research Services, Epistem Ltd Maria Torvinen, Field Application Scientist,Corning
You will benefit from attending this event if you are:
A Vice President, Director or Group Leader from within the pharmaceutical or biotech industry with responsibilities in the following areas:
- Disease profiling
- Drug target discovery / validation
- Drug discovery
- ADMET
- Preclinical development
- Pharmacokinetics
- Drug metabolism
- Toxicology
- Clinical research
- Screening
- Functional genomics
| - Medicinal chemistry
- Lead optimisation
- Structural biology
- Molecular and cell biology
- Proteomics
- Biopharmaceuticals research
- Bioanalytical development
- Kinase and GPCR assays
- Diagnostics
- Bioassay development / optimisation
|
|
Events Home Page
.jpg)
